Pacific Biosciences Of California (PACB) Common Equity (2010 - 2026)

Pacific Biosciences Of California has reported Common Equity for 17 years, with the latest figure at -$33.2 million in Q2 2026.

• On a quarterly basis, Common Equity fell 154.01% year-over-year to -$33.2 million in Q2 2026; TTM through Jun 2026 was -$33.2 million, a 154.01% decrease from a year earlier, with the FY2025 full-year figure at $5.3 million, down 98.94% from the prior year.
• Common Equity was -$33.2 million for Q2 2026 at Pacific Biosciences Of California, down from $2.4 million in the prior quarter.
• The five-year high for Common Equity was $763.7 million in Q3 2023, with the low at -$33.2 million in Q2 2026.
• Average Common Equity over 5 years is $426.1 million, with a median of $534.7 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: Common Equity surged 164.05% in 2022, then plunged 154.01% in 2026.
• Over 5 years, Common Equity stood at $562.9 million in 2022, then increased by 24.59% to $701.3 million in 2023, then dropped by 27.76% to $506.6 million in 2024, then tumbled by 98.94% to $5.3 million in 2025, then tumbled by 720.92% to -$33.2 million in 2026.
• The last three Common Equity figures came in at -$33.2 million (Q2 2026), $2.4 million (Q1 2026), and $5.3 million (Q4 2025), per Business Quant data.